Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - April 2014


2nd Annual Biosimilars & Biobetters Congress 2014

03 Apr 2014 - 04 Apr 2014



Bookmark and Share


Over 400 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions

25 presentations, case studies and panel discussions focused on the key issues in follow-on biologics development and commercialisation

2 interactive streams:

  • Market Opportunities and Commercial Challenges
  • Developing Biosimilars and Biobetters

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

Co-located with the 7th Annual Proteins & Antibodies Congress & the Peptides Congress Oxford Global are proud to present the Biosimilars & Biobetters Congress, taking place on 3-4 April 2014 at Novotel London West, UK.

The follow on biologics industry is forecast to reach $8.8 billion by 2017. Our conference programme focuses on the challenges, innovations and technologies that promise to put this sector at the forefront of the pharmaceutical industry.

The 2nd Annual Biosimilars and Biobetters Congress features two streams:

Market Opportunities & Commercial Challenges: In Stream 1, the meeting will address the most pressing challenges in gaining access to emerging markets and branding biosimilars through a series of cutting-edge conference presentations. Our boisimilars experts will also debate how to overcome regulatory challenges, outsource manufacturing and develop pricing strategies

Developing Biosimilars & Biobetters: Learn more about current developments in clinical trials, including pharmacovigilence and patient safety. Do not miss out on the chance to discover innovative solutions for achieving quality by design, demonstrating biosimilarity and addressing potency as well as the latest insights into the regulatory requirements and trial design.

The Biosimilars & Biobetters Congress is part of the highly successful Oxford Global Proteins Series.

Further information
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
Engineering Foe into Friend
Bose Grant awardee Jacquin Niles aims to repurpose the malaria parasite for drug delivery.
Important Regulator of Immune System Decoded
Plasma cells play a key role in our immune system. Now scientists at the Research Institute of Molecular Pathology (IMP) in Vienna, Austria, and at the Walter and Eliza Hall Institute (WEHI) in Melbourne, Australia, succeeded in characterizing a central regulator of plasma cell function.
Bacterial Superglue for Faster Vaccine Development
An interdisciplinary team of Oxford University researchers has devised a new technique to speed up the development of novel vaccines.
Enumeral, MD Anderson Enter Into Collaboration
Strategic collaboration aims to discover and develop potentially novel antibodies against specified targets for immunotherapy.
Joint venture for GlycoMar Limited and MicroA AS
Scottish biotechnology company GlycoMar and Norwegian technology company MicroA are pleased to announce their joint venture business Prasinotech Ltd. The new company is registered in Scotland.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!